Frontotemporal Dementia

The grounding supports a genetic subset caused by loss-of-function mutations in the progranulin gene (GRN), which lower progranulin levels and are associated with frontotemporal dementia. The literature also links frontotemporal dementia with TDP-43 proteinopathy and shared disease etiology with amyotrophic lateral sclerosis, but it does not support a single universal cause.

The disease is associated with neurodegenerative pathology affecting neural circuits that support behavior and executive control. Co-studied proteins and reviews point to TDP-43 pathology, including cytoplasmic inclusion bodies of phosphorylated and truncated TDP-43 in a subset of frontotemporal lobar degeneration, and to progranulin-related microglial dysfunction in GRN-associated disease.

Genetic variation is a supported risk factor, particularly loss-of-function mutations in GRN. The grounding also supports overlap with TDP-43 proteinopathy and shared neurodegenerative biology with ALS, but it does not provide broader epidemiologic risk factors.

The supplied grounding does not describe established treatment for frontotemporal dementia. It only supports research directions such as immuno-neurology and targeting progranulin as a therapeutic approach, without enough detail to define standard clinical care.